We use cookies to ensure that we give you the best experience on our website Learn more

May 20, 2019

87th EAS Congress

05 - LIPID-LOWERING RESPONSE IN SUBJECTS WITH THE P.(LEU167DEL) MUTATION IN APOE GENE

;

APOE

p.(Leu167del)

familial hypercholesterolemia

lipid-lowering treatment

Abstract

Abstract

thumbnail

Keywords

APOE

p.(Leu167del)

familial hypercholesterolemia

lipid-lowering treatment

Abstract

Background and aim The aim of this work was to compared the effect of lipid lowering drugs among FH subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE. Methods We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n=22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n=44). Results The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4 % and -36.4%, respectively (p = 0.030). Conclusions Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for more efficient management of FH.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.